OM:HM B
OM:HM BSpecialty Retail

Is H&M (OM:HM B) Overvalued After Its Recent Share Price Rebound? A Closer Look at the Valuation

H & M Hennes & Mauritz (OM:HM B) has been quietly rewarding patient shareholders, with the stock gaining about 22% over the past 3 months and roughly 20% year to date. See our latest analysis for H & M Hennes & Mauritz. At around SEK 178.65 per share, the 90 day share price return of about 22% and a three year total shareholder return above 80% suggest momentum is clearly building again as investors warm to H & M Hennes & Mauritz’s recovery story. If H & M’s rebound has you rethinking retail,...
OM:SAAB B
OM:SAAB BAerospace & Defense

Assessing Saab (OM:SAAB B) Valuation After Breakthrough Autonomous Aircraft Fuselage Milestone with Divergent Technologies

Saab (OM:SAAB B) just hit an interesting milestone with Divergent Technologies, delivering initial autonomous aircraft fuselages built using fully digital, additive manufacturing. For investors, this is less about near term revenue and more about long term capability. See our latest analysis for Saab. That milestone with Divergent lands after a busy spell for Saab, with fresh Spanish Army training contracts and another Lithuanian MSHORAD order. It comes on top of a powerful year to date share...
OM:BONEX
OM:BONEXBiotechs

Shifting CERAMENT V To FDA De Novo Review Might Change The Case For Investing In Bonesupport Holding (OM:BONEX)

BONESUPPORT has already shifted its U.S. regulatory route for CERAMENT V for bone infection from a 510(k) submission to the FDA’s De Novo pathway, extending the formal review period from 90 to 150 days while transferring substantial existing clinical and pharmacological documentation. This move suggests CERAMENT V could, if cleared, create a new product category in the U.S., echoing how CERAMENT G previously established a distinct regulatory class and potentially underscoring the uniqueness...
OM:SKA B
OM:SKA BConstruction

Is It Too Late To Consider Skanska After Contract Wins And Strong Multi Year Share Gains

Wondering if Skanska is still good value after its run over the last few years, or if most of the upside is already priced in? This breakdown will help you decide whether to keep watching or start acting. The stock has climbed about 2.0% over the last week, 3.3% year to date and 9.3% over the past year, while its 3 year gain of 60.9% and 5 year gain of 44.6% show that investors have already been rewarded for backing the story. Recent headlines have focused on Skanska winning new...
OM:BRAV
OM:BRAVCommercial Services

Bravida (OM:BRAV) Lands SEK 25m Media Contract — Is the Stock Undervalued on Rebuilding Momentum?

Bravida Holding (OM:BRAV) just landed a nationwide framework contract with Sveriges Radio, Sveriges Television and Sveriges Radio Förvaltning, a SEK 25 million deal that quietly reinforces its role in Sweden’s critical media infrastructure. See our latest analysis for Bravida Holding. The contract news fits into a picture of quietly improving sentiment, with the latest share price at SEK 85.95 and a solid year to date share price return contrasting with weaker three year total shareholder...
OM:EMBRAC B
OM:EMBRAC BEntertainment

Does Embracer Group’s Coffee Stain Spin-Off Clarify Its Core Strategy Or Complicate It (OM:EMBRAC B)?

Embracer Group’s recent Extraordinary General Meeting approved the past distribution of its subsidiary Coffee Stain Group AB, granting shareholders one Coffee Stain share per Embracer share, with Coffee Stain’s class B shares now trading on Nasdaq First North Premier Growth Market Sweden under ticker COFFEE B. This spin-off reshapes Embracer’s portfolio by separating a key gaming asset, giving investors direct exposure to Coffee Stain while potentially clarifying the value of Embracer’s...